Companies › Aclaris Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATI-045 | – | Phase 2 | Atopic Dermatitis | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07011706 | ATI-045 | Phase 2 | Atopic Dermatitis | Immunology | Nov 2026 |
Cash and short-term investments of $205m on 2026-09-30; operating cash outflow about $83m a year; runway about 30 months at that burn, to Mar 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Palisade Bio Quoin Pharmaceuticals Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.